Welcome to Boulos & Cooper Pharmaceuticals
We recognise the magnitude of the antibiotic resistance crisis, and are committed to being a part of the solution to address a global concern. We are doing this by developing a new class of antibiotics with novel mechanisms of action. Our antibiotics target the novel mechanosensitive ion channel of large conductance (MscL), a much desired antibacterial target. This channel has a high level of conservation in bacteria and is absent from the human genome.
Mechanosensitive channels act as gatekeepers, protecting bacterial cells against lysis following an osmotic downshock. Our antibiotics work by lowering the threshold at which the channels activate and increasing the probability of the channel opening. In essence, our antibiotics “induce vomiting in bacteria”, challenging their survival.